Minimal residual disease assessment and progress in multiple myeloma
10.3760/cma.j.cn121090-20230728-00036
- VernacularTitle:多发性骨髓瘤微小残留病检测与应用进展
- Author:
Huixing ZHOU
1
;
Wenming CHEN
Author Information
1. 首都医科大学附属北京朝阳医院血液科，北京市多发性骨髓瘤医疗研究中心，北京 100020
- From:
Chinese Journal of Hematology
2024;45(2):203-208
- CountryChina
- Language:Chinese
-
Abstract:
With the rapid iteration of multiple myeloma therapeutics over the last two decades, as well as increasing remission rates and depth of remission in patients, traditional methods for monitoring disease response are insufficient to meet the clinical needs of new drugs. Minimal residual disease (MRD) is a more sensitive test for determining the depth of response, and data from multiple clinical trials and meta-analyses show that a negative MRD correlates with a better prognosis than a traditional complete response. MM is at the forefront of MRD evaluation and treatment. MRD detection methods have been continuously updated. The current MRD assessment has three dimensions: bone marrow-based MRD testing, MRD testing based on images of residual metabolic of focal lesions, and peripheral blood-based MRD testing. The various MRD assessment methods complement one another. The goal of this article is to discuss the currently used MRD assays, the progress, and challenges of MRD in MM, and to provide a reference for clinicians to better use the techniques.
